In this episode, Dr. Kahn kicks off with some motivating insights from recent research showing that climbing stairs can lower death rates. He then explores two new studies highlighting the benefits of creatine and roasted green tea (hojicha) for brain performance. Find creatine here: Dr. Joel Kahn's Creatine Capsules.

Dr. Kahn also delves into the roles of growth hormone (GH) and insulin-like growth factor 1 (IGF-1) in health and disease, focusing on Laron Syndrome. This rare condition involves life-long low levels of IGF-1, leading to shorter stature but also lower rates of diabetes, cancer, and heart disease. He discusses how the Prolon Fasting Mimicking Diet and the new L-Protein can help regulate IGF-1 for better health. Check them out here: Prolon FMD by Dr. Kahn.

This week, Dr. Kahn explores a variety of "mini-topics," including the presence of microplastics in fish, the link between heart disease and cancer, the ineffectiveness of the ketogenic diet for cardiovascular disease, and the lifetime risk and consequences of atrial fibrillation.

Dr. Kahn also embraces the theme of "fighting heart disease like cancer" by presenting case studies from two recent patients at the Kahn Center for Cardiac Longevity, showcasing the center's approach to aggressive treatment that mirrors cancer care norms.

Welcome to Heart Doc VIP! This week, Dr. Kahn tackles a series of mini-topics including the use of colchicine in treating heart disease, the crucial role of oral health in managing atrial fibrillation, and why beta-blockers may not benefit many heart attack patients.

Plus, hear Dr. Kahn's thoughts on Valter Longo, Ph.D.'s insights about the "5Ps" that are excessively present in our diets. Also, check out the newly available L-Protein, a plant-based protein, at prolonfmd.com/Drkahn.

Our main discussion centers on the recent findings from the TACT2 trial, where intravenous chelation therapy in 1,000 heart patients followed over four years failed to improve outcomes. This result is particularly disheartening following the promising TACT trial published in 2013, and it likely signals the end of funded research for chelation therapy.